# CARES (NCT04504825)

> A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04504825
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alexion Pharmaceuticals, Inc.
- Conditions: AL Amyloidosis
- Interventions: CAEL-101; Placebo; cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Enrollment: 125
- Primary outcome: A Hierarchical Combination of Time to All-cause Mortality and Frequency of Cardiovascular Hospitalizations (CVHs) Analyzed by Win Ratio
- Primary outcome: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

## Indexed commentary on CARES so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cares-nct04504825